-
Real-World Impact of Olaparib in BRCA-Mutant Advanced Pancreatic Cancer
A new study published in Cancer Medicine by Michele Milella, Giulia Orsi, Mariacristina di Marco, Lisa Salvatore, and colleagues highlights the real-world survival benefits of olaparib in patients with BRCA1/2-mutant metastatic pancreatic cancer (PDAC). Conducted across 23 Italian oncology centers, the analysis revealed that patients exposed to olaparib at any point during their treatment course…
-
Sara Tolaney’s Latest Contribution to HER2-Positive Breast Cancer Treatment
Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, continues to lead the research in HER2-positive breast cancer. In her latest study, published in Journal…
-
Mark Robson’s Contribution to BRCA2 Variant Classification in Breast Cancer
Dr. Mark E. Robson, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, continues to lead research in breast cancer genetics. In a January 2025 Nature publication,…
-
Gene Signatures for Personalized Treatment in Colorectal Cancer
A new study published in Communications Medicine highlights the potential of gene signatures derived from transcriptomic-causal networks to improve patient stratification for targeted therapy in metastatic colorectal cancer (mCRC). By integrating gene interconnectivity into survival analysis, researchers identified distinct gene signatures that predict response to cetuximab or bevacizumab, providing a more personalized approach to treatment.
-
Christian Labenz’s Contribution to Research on Cognitive Impairment in Cirrhosis and Diabetes
Cognitive dysfunction is a major concern in cirrhotic patients, especially those at risk of hepatic encephalopathy (HE). Diabetes mellitus, a common comorbidity, has been linked to increased HE risk, raising…
-
Reminder: Capivasertib and Endocrine Resistance in HR+ Breast Cancer
Endocrine resistance remains a key challenge in HR+/HER2- advanced breast cancer, particularly after progression on CDK4/6 inhibitors. The CAPItello-291 trial, published in The New England Journal of Medicine (2023), highlighted…
-
Avelumab in High-Grade Neuroendocrine Tumors: Insights from the AveNEC Trial
The Phase II AveNEC trial, published in Clinical Cancer Research (February 2025), evaluated avelumab in patients with high-grade neuroendocrine neoplasms (NEN G3) who had progressed after prior chemotherapy. The study…
-
BREAKWATER Phase 3 Trial: A New Standard for First-Line BRAF V600E-Mutant mCRC Treatment
The BREAKWATER phase 3 trial, published in Nature Medicine, has demonstrated that encorafenib plus cetuximab (EC) with mFOLFOX6 significantly improves objective response rates compared to standard chemotherapy in BRAF V600E-mutant metastatic colorectal cancer (mCRC). The study reports a confirmed objective response rate of 60.9% with EC+mFOLFOX6 compared to 40.0% with standard chemotherapy, with a median…
Connecting Medical Expertise through Media